Clinical Trial Update: Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update comparing erlotinib to gemcitabine/cisplatin as (neo)adjuvant treatment for non-small cell lung cancer across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• gemcitabine/cisplatin

Snippet

Sponsor: Guangdong Association of Clinical Trials | Conditions: Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN